1 August 2018 - The August 2018 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The August issue of the Schedule includes a number of new/revised listings:

• Aclidinium bromide with eformoterol fumarate dihydrate (Brimica Genuair) - restriction change
• Follitropin delta (Rekovelle) - new medicine
  
• Glecaprevir with pibrentasvir (Maviret) - new combination product
  
• Ibrutinib (Imbruvica) - new indication
  
• Indacaterol maleate with glycopyrronium bromide (Ultibro Breezhaler) - restriction change
• Insulin degludec with insulin aspart (Ryzodeg) - new combination product
  
• Nivolumab (Opdivo) - new indication
  
• Peginterferon alfa-2a (Pegasys) - new indication
  
• Perampanel hemisesquihydrate (Fycompa) - new indication
  
• Pirfenidone (Esbriet) - new strength
  
• Tiotropium bromide monohydrate with olodaterol hydrochloride (Spiolto Respimat) - restriction change
  
• Vilanterol trifenatate with umeclidinium bromide (Anoro Ellipta) - restriction change
  

Read Summary of Changes